Press Release

KDA Group announces shares issuance

Thetford Mines, June 29, 2017 – KDA Group Inc. (TSXV : KDA) (“KDA Group” or the “Corporation”) announced today the issuance of 250,000 Class A shares of its share capital to Joddes Limited within the context of an internal reorganization pursuant to which KDA Group acquired all the outstanding shares of its indirect subsidiary Biomed (2002) Inc., which was held at 90 % by Pharmapar, a KDA subsidiary, and at 10 % by Joddes Limited.

AlliancePharma Becomes KDA Group

THETFORD MINES, QUEBEC–(Marketwired – Jan. 31, 2017) – AlliancePharma Inc. (TSX VENTURE:APA) (“AlliancePharma” or the “Corporation“) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders held on January 25, 2017 and its name change to KDA Group Inc.

AlliancePharma Announces Closing of Previously Announced Private Placement with Persistence Capital Partners

THETFORD MINES, QUEBEC–(Marketwired – Oct. 20, 2016) – AlliancePharma Inc. (TSX VENTURE:APA) (“AlliancePharma” or the “Corporation“) is pleased to announce that it has issued an aggregate of 40 000 Series A Preferred Shares to Persistence Capital Partners in connection with the $4,000,000 private placement previously announced on July 4, 2016 (the “Private Placement“).

AlliancePharma Announces Appointment of New Director

THETFORD MINES, QUEBEC–(Marketwired – Aug. 26, 2016) – AlliancePharma Inc. (TSX VENTURE:APA) (“AlliancePharma” or the “Corporation“) is pleased to announce the appointment of Dr. Sheldon Elman as a member of the board of directors of the Corporation. Dr. Elman is the Founder and Chairman of Medisys Health Group Inc., Canada’s leading provider of comprehensive, preventive and corporate health solutions, as well as a Founding Partner of Persistence Capital Partners, a private equity fund specializing in health care. “I am very excited that Dr. Elman has joined the board of directors of AlliancePharma,” said Marc Lemieux, President and CEO of AlliancePharma. “Dr. Elman brings a great deal of board experience as well as extensive knowledge in the healthcare industry.”

AlliancePharma Completes Previously Announced Transformative Acquisitions

THETFORD MINES, QUEBEC–(Marketwired – Aug. 23, 2016) – AlliancePharma Inc. (TSX VENTURE:APA) (“AlliancePharma” or the “Company“) is pleased to announce that it has completed the previously announced acquisitions of Pharmapar Inc. and Agence L.I.V. Inc. These transformative transactions position AlliancePharma for the next stage of its corporate development. The Company now has approximately 100 employees, a network of over 750 allied health professional contractors, 1,100 clients, annual gross sales of over $50 million and pro-forma Adjusted EBITDA of approximately $5 million.

AlliancePharma Announces Transformative Acquisitions

THETFORD MINES, QUEBEC–(Marketwired – July 4, 2016) – AlliancePharma Inc. (TSX VENTURE:APA) (“AlliancePharma” or the “Corporation“) is pleased to announce that it has entered into definitive agreements to acquire three companies and has also entered into a private placement agreement with a healthcare-focused private equity fund. These transformative transactions will position AlliancePharma for the next stage of its corporate development. Assuming the completion of these transactions, AlliancePharma will have approximately 100 employees, a network of over 750 allied health professional contractors, 1,100 clients and annual gross sales of over $50 million.

Groupe KDA © 2019. Tous droits réservés.